Fmoc-L-2-aminobutyric acid

Fmoc-L-2-aminobutyric acid is an Fmoc-protected L-amino acid featuring a chiral 2-aminobutyric acid backbone with an Fmoc carbamate on the nitrogen and a free carboxylic acid for controlled coupling at the peptide C-terminus. The side chain is a branched aliphatic unit (2-ethyl substituent pattern relative to the alpha carbon), providing steric modulation and hydrophobic character that can influence peptide conformation and binding-site recognition. The Fmoc group is base-labile and supports standard solid-phase or solution-phase peptide assembly, while the carboxylic acid enables activation to form amide bonds with compatible nucleophiles. The stereodefined L-configuration and orthogonality of the Fmoc protecting strategy make it a practical chiral building block for amino acid derivatization and downstream synthetic intermediate formation.

1. Peptide Synthesis

Fmoc-L-2-aminobutyric acid is used in peptide synthesis as an Fmoc-protected amino acid building block for stepwise peptide coupling, where the Fmoc carbamate supports orthogonal protection during chain elongation. The free carboxylic acid and stereodefined alpha-amino center enable amide bond formation with activated carboxyl derivatives or peptide-resin-bound nucleophiles under peptide coupling conditions. The branched aliphatic side chain can be incorporated to tune local sterics, backbone hydration, and helix or turn propensity in peptide analogs. Peptide producers and research groups can apply it to generate sequence-defined peptides and peptidomimetics that require a noncanonical, hydrophobic residue with predictable stereochemistry.

2. Peptidomimetics And SAR

Fmoc-L-2-aminobutyric acid serves in peptidomimetic construction and structure-activity relationship studies by introducing a stereodefined, branched aliphatic side chain that can modulate conformational preferences and molecular recognition. The Fmoc-protected amine allows controlled incorporation into peptide-like scaffolds, while the carboxylic acid functionality supports conversion into amide-linked analogs or further derivatization prior to or after assembly. Side-chain sterics and hydrophobicity can be leveraged to probe binding-site tolerance for subtle changes in residue volume and shape. Downstream analog libraries can be generated by using this residue as a standardized chiral intermediate in medicinal chemistry workflows focused on SAR mapping and scaffold optimization.

3. Protected Amino Acid Chemistry

Fmoc-L-2-aminobutyric acid is suitable for protected amino acid chemistry and intermediate preparation because it combines a base-labile Fmoc group with a reactive carboxylic acid handle for selective transformations. The Fmoc strategy enables temporary protection of the alpha-amino functionality during synthesis, while the carboxylic acid can be activated for coupling, esterification for solubility tuning, or conversion to activated derivatives for controlled downstream use. The L-stereochemistry provides a defined chiral center that is retained through amide bond formation and most carboxyl activation steps. Synthetic teams can employ the compound as a chiral amino acid intermediate to access N-protected derivatives, sequence-defined building blocks, and peptide coupling-ready reagents for fine chemical production.

4. Chemical Biology Labeling

Fmoc-L-2-aminobutyric acid can be applied in chemical biology workflows that require residue-level control within peptide probes and labeling reagents. The Fmoc-protected amine supports incorporation into probe backbones, and the carboxylic acid enables subsequent functional group manipulation to introduce conjugation-ready motifs through amide-linked linkers. The branched aliphatic side chain can help tune probe hydrophobicity and reduce nonspecific interactions in complex biological matrices, supporting reproducible behavior of peptide-based reagents. Bioconjugation chemists can use this amino acid building block to prepare peptide conjugates that serve as substrates for downstream click chemistry, affinity tagging, or analytical detection strategies.

5. Pharmaceutical Manufacturing Intermediates

Fmoc-L-2-aminobutyric acid is relevant to pharmaceutical manufacturing and process chemistry as a reproducible chiral intermediate for producing Fmoc-based peptide intermediates under scalable synthetic routes. The Fmoc carbamate provides robust protection during handling and coupling steps, while the free carboxylic acid enables conversion to activated forms compatible with manufacturing-grade peptide assembly. The defined L-configuration and stable protecting-group behavior support consistent stereochemical outcomes across batch production of peptide drug candidates or peptide excipients. Process developers can incorporate this residue into standardized intermediate sets to streamline peptide construction, purification planning, and downstream conversion to final peptide materials.

6. Analytical Research Standards

Fmoc-L-2-aminobutyric acid is used in analytical research as a reference material and derivatization component for method development involving amino acid and peptide analysis. The combination of Fmoc protection and a free carboxylic acid provides a defined chemical signature that can be tracked by chromatographic and mass spectrometric workflows during peptide synthesis monitoring or amino acid composition verification. The stereodefined L-form supports chiral-aware analytical strategies when separating or confirming amino acid stereochemistry in complex peptide mixtures. Analytical laboratories can employ the compound to validate sample preparation, calibration, and identity checks for peptide building block incorporation and protected amino acid chemistry performance.

1. Cationic cell-penetrating peptides are potent furin inhibitors

2. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

4. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes